History of MSD

MSD and Schering-Plough merged in 2009 to become a wholly owned subsidiary of Merck & Co. Inc. In all markets apart from the United States and Canada, we are known as MSD.

Both MSD and Schering-Plough have a long and rich history of working to improve people's health and well-being.

Through the years, our researchers have helped to find new ways to treat and prevent illness. During the first nine months of WWll, MSD was the only company prepared to supply dried plasma to the armed forces. This development saved thousands of men’s lives and was one of the outstanding medical contributions to the war effort.

The company discovered vitamin B1 and began producing penicillin “G” in 1942, as well as the first measles vaccine, the most widely prescribed statins to treat high cholesterol and the first anti-cancer vaccine.

Merck & Co, Inc. scientists were among the first to discover and develop medicines for the treatment of HIV/AIDS.

In 1996, MSD introduced a protease inhibitor and one of the first potent antiretroviral drugs. The introduction of a non-nucleoside reverse transcriptase inhibitor (NNRTI), followed in 1999.

Merck & Co, Inc. recently developed a vaccine for Ebola. This vaccine was advanced through clinical trials in record time and the company subsidised all R&D.